Literature DB >> 16267570

RNA knockdown as a potential therapeutic strategy in Parkinson's disease.

F P Manfredsson1, A S Lewin, R J Mandel.   

Abstract

Parkinson's disease is a prevalent progressive degenerative disorder of the elderly. There is a current need for novel therapeutic strategies because the standard levodopa pharmacotherapy is only temporarily efficacious. Recently, there have been some high-profile successful preclinical results obtained in animal models of neurological disorders using small interfering RNAs delivered by viral vectors. RNA interference can theoretically be applied to Parkinson's disease since over-expression of various proteins is known to kill the dopamine neurons of the substantia nigra in animal models and in familial forms of Parkinson's disease. Potential RNA interfering strategies and caveats are discussed in this review. Gene Therapy (2006) 13, 517-524. doi:10.1038/sj.gt.3302669; published online 3 November 2005.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16267570     DOI: 10.1038/sj.gt.3302669

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

Review 1.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 2.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

Review 3.  Nanoparticle transport across the blood brain barrier.

Authors:  Andreas M Grabrucker; Barbara Ruozi; Daniela Belletti; Francesca Pederzoli; Flavio Forni; Maria Angela Vandelli; Giovanni Tosi
Journal:  Tissue Barriers       Date:  2016-02-25

Review 4.  Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

Authors:  S K Kalia; L V Kalia; P J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

5.  Silencing of Hsp90 chaperone expression protects against 6-hydroxydopamine toxicity in PC12 cells.

Authors:  Behrang Alani; Rasoul Salehi; Payam Sadeghi; Mohammad Zare; Fariba Khodagholi; Ehsan Arefian; Mazdak Ganjalikhani Hakemi; Hadi Digaleh
Journal:  J Mol Neurosci       Date:  2014-03       Impact factor: 3.444

Review 6.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

7.  The involvement of Eag1 potassium channels and miR-34a in rotenone-induced death of dopaminergic SH-SY5Y cells.

Authors:  Camila Hillesheim Horst; Ricardo Titze-de-Almeida; Simoneide Souza Titze-de-Almeida
Journal:  Mol Med Rep       Date:  2017-02-10       Impact factor: 2.952

8.  Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer Cells.

Authors:  Matomo Sakari; Takeshi Suzuki; Seiji Yano; Toshifumi Tsukahara
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

Review 9.  Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.

Authors:  Della Grace Thomas Parambi; Khalid Saad Alharbi; Rajesh Kumar; Seetha Harilal; Gaber El-Saber Batiha; Natália Cruz-Martins; Omnia Magdy; Arafa Musa; Dibya Sundar Panda; Bijo Mathew
Journal:  Mol Neurobiol       Date:  2021-10-15       Impact factor: 5.682

10.  Development of elastin-like polypeptide for targeted specific gene delivery in vivo.

Authors:  Aena Yi; Dahye Sim; Young-Jin Lee; Vijaya Sarangthem; Rang-Woon Park
Journal:  J Nanobiotechnology       Date:  2020-01-17       Impact factor: 10.435

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.